Bulletin
Investor Alert

London Markets Open in:

Teva Pharmaceutical Industries Ltd. ADR

NYS: TEVA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 1, 2022, 7:58 p.m.

/zigman2/quotes/205657894/composite

$

7.79

Change

-0.10 -1.27%

Volume

Volume 80,800

Quotes are delayed by 20 min

/zigman2/quotes/205657894/composite

Previous close

$ 7.52

$ 7.89

Change

+0.37 +4.92%

Day low

Day high

$7.42

$7.91

Open

52 week low

52 week high

$7.23

$10.50

Open

Company Description

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates...

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Valuation

P/E Current

21.94

P/E Ratio (without extraordinary items)

22.05

Price to Sales Ratio

0.58

Price to Book Ratio

0.93

Price to Cash Flow Ratio

3.78

Enterprise Value to EBITDA

6.78

Enterprise Value to Sales

1.93

Total Debt to Enterprise Value

0.74

Efficiency

Revenue/Employee

1,363,661.00

Income Per Employee

35,884.00

Receivables Turnover

3.55

Total Asset Turnover

0.33

Liquidity

Current Ratio

1.14

Quick Ratio

0.79

Cash Ratio

0.20

Profitability

Gross Margin

47.10

Operating Margin

19.36

Pretax Margin

4.15

Net Margin

2.63

Return on Assets

0.87

Return on Equity

4.20

Return on Total Capital

8.67

Return on Invested Capital

1.30

Capital Structure

Total Debt to Total Equity

229.31

Total Debt to Total Capital

69.63

Total Debt to Total Assets

49.44

Long-Term Debt to Equity

214.37

Long-Term Debt to Total Capital

65.10

Officers and Executives

Name Age Officer Since Title
Mr. Kåre Schultz 59 2017 President, Chief Executive Officer & Director
Dr. Eric Drapé 59 2013 Executive Vice President-Global Operations
Mr. Eli Kalif 48 2019 Chief Financial Officer & Executive Vice President
Ms. Lori A. Queisser 60 2015 Senior Vice President & Global Compliance Officer
Mr. John Nason - 2015 President-Biologics Operations

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/10/2018 Bridger Management LLC
Director
250,000   Acquisition at $19.32 per share. 4,830,000
05/09/2018 Bridger Management LLC
Director
500,000   Acquisition at $19.21 per share. 9,605,000
/news/latest/company/us/teva

MarketWatch News on TEVA

  1. Teva to pay $75 mln over 15 years to settle opioid claims from W. Va., plus pay $8 mln in legal fees

    9:46 a.m. May 25, 2022

    - Steve Gelsi

  2. Teva settlement with W. Va. also includes $27 mln worth of generic Narcan over 10 years

    9:46 a.m. May 25, 2022

    - Steve Gelsi

  3. W. Va. says Teva opioid agreement consistent with previously announced settlements

    9:46 a.m. May 25, 2022

    - Steve Gelsi

  4. Teva Pharmaceutical upgraded to neutral from underperform at BofA Securities

    9:36 a.m. May 17, 2022

    - Tomi Kilgore

  5. Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion

    10:06 a.m. May 10, 2022

    - Barron's Online

  6. Teva CEO Sees a Final Opioid Settlement Coming This Year

    4:58 p.m. May 3, 2022

    - Barron's Online

  7. Teva now sees full-year revenue of $15.4 bln to $16.0 bln vs. prior guidance of $15.6 bln to $16.2 bln

    7:19 a.m. May 3, 2022

    - Ciara Linnane

  8. Teva now sees full-year EPS of $2.40 to $2.60, unchanged vs. prior guidance

    7:20 a.m. May 3, 2022

    - Ciara Linnane

  9. Teva lowers full-year revenue guidance

    7:19 a.m. May 3, 2022

    - Ciara Linnane

  10. Teva Q1 adj. EPS 55 cents; FactSet consensus 53 cents

    7:17 a.m. May 3, 2022

    - Ciara Linnane

  11. Teva Q1 revenue $3.661 bln, down 8%; FactSet consensus $3.598 bln

    7:18 a.m. May 3, 2022

    - Ciara Linnane

  12. Teva Q1 loss per share 86 cents vs. EPS 7 cents a year ago

    7:17 a.m. May 3, 2022

    - Ciara Linnane

  13. Teva, Others to Pay Millions in Florida Opioid Settlements

    12:43 p.m. March 30, 2022

    - Barron's Online

  14. Teva Pharmaceutical upgraded to outperform at Bernstein

    1:38 p.m. March 25, 2022

    - Tomi Kilgore

  15. Loading more headlines...
/news/nonmarketwatch/company/us/teva

Other News on TEVA

  1. 2 Biotech Stocks That Could Soar in the Third Quarter

    5:41 a.m. July 2, 2022

    - Motley Fool

  2. Teva names new medical chief

    9:28 a.m. July 1, 2022

    - Seeking Alpha

  3. CVS, Walmart Impose Purchase Limits on Plan B Pills

    12:12 p.m. June 28, 2022

    - Sharon Terlep

  4. Teva Lonquex gets EMA panel backing for expanded use in children

    10:28 a.m. June 24, 2022

    - Seeking Alpha

  5. Teva started at neutral at UBS on pricing and legal concerns

    12:18 p.m. June 14, 2022

    - Seeking Alpha

  6. Loading more headlines...

At a Glance

Teva Pharmaceutical Industries Ltd.

124 Dvora HaNevi'a Street

Tel Aviv, TA 6944020

Phone

972 39148213

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$51.19B

Net Income

$1.35B

Employees

37,537

/news/pressrelease/company/us/teva

Press Releases on TEVA

  1. Teva Pharmaceutical (TEVA) Trading Report

    5:27 p.m. June 30, 2022

    - Stock Traders Daily

  2. Teva Pharmaceutical TEVA Proactive Strategies

    10:36 p.m. June 20, 2022

    - Stock Traders Daily

  3. Migraine Treatment Drugs Market Size, Share | Global Report [2028]

    12:58 a.m. June 16, 2022

    - AmericaNewsHour

  4. Learn to Evaluate Teva Pharmaceutical (TEVA) using the Charts

    11:12 p.m. June 9, 2022

    - Stock Traders Daily

  5. Teva Pharmaceutical (TEVA) Trading Report

    3:07 a.m. May 31, 2022

    - Stock Traders Daily

  6. Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls

    7:45 a.m. May 21, 2022

    - Stock Traders Daily

  7. Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls

    7:45 a.m. May 21, 2022

    - Stock Traders Daily

  8. Loading more headlines...
Link to MarketWatch's Slice.